Literature DB >> 18375242

Comprehensive lipid management versus aggressive low-density lipoprotein lowering to reduce cardiovascular risk.

Robert H Knopp1, Pathmaja Paramsothy, Benjamin Atkinson, Alice Dowdy.   

Abstract

Five lines of evidence justify comprehensive lipoprotein management over aggressive low-density lipoprotein (LDL) lowering alone in most cases of cardiovascular disease (CVD) prevention. First, lipoprotein lipid transport consists of a single, recycling system involving very-low-density lipoprotein, LDL, and high-density lipoprotein (HDL). Single lipid interventions affect all lipoprotein classes to varying degrees. These effects can be expanded by using different drug classes in combination. Second, observational studies support the unitary nature of lipoprotein risk. A family of curves describes increasing CVD risk from increasing LDL as other risk factors are present. Conversely, a family of curves describes increasing CVD risk from decreasing levels of HDL in mirror image to LDL. The LDL and HDL risks are additive. Third, clinical trials that raise HDL and lower triglyceride ameliorate CVD, as does lowering LDL. Lowering LDL prevents heart disease, but by only 22%-36% with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor therapy. Studies indicate that better CVD prevention is obtained when drugs for triglyceride and HDL reduction are combined with LDL reduction. Fourth, HDL and its apolipoprotein (apo), apo A-I, as well as apo A-I analogues, decrease atherosclerosis. Each modality decreases atherosclerosis in animal models, and apo A-I Milano acutely decreases human coronary luminal stenosis. Apo A-I analogues have similar promise. Fifth, combined hyperlipidemia is the most common lipid disorder, has the strongest risk for CVD, and combines elevated LDL, hypertriglyceridemia, and low HDL. This condition requires the comprehensive treatment approach described above. In conclusion, 5 lines of evidence justify comprehensive diet and drug treatment for combined hyperlipidemia and, at lesser LDL elevations, the atherogenic dyslipidemias of obesity, diabetes mellitus, and the metabolic syndrome.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18375242     DOI: 10.1016/j.amjcard.2008.02.038

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

1.  Comparative Effectiveness and Toxicity of Statins Among HIV-Infected Patients.

Authors:  Sudershan Singh; James H Willig; Michael J Mugavero; Paul K Crane; Robert D Harrington; Robert H Knopp; Bradley W Kosel; Michael S Saag; Mari M Kitahata; Heidi M Crane
Journal:  Clin Infect Dis       Date:  2010-12-28       Impact factor: 9.079

2.  Cholesterol absorption and synthesis markers in individuals with and without a CHD event during pravastatin therapy: insights from the PROSPER trial.

Authors:  Nirupa R Matthan; Nancy Resteghini; Michele Robertson; Ian Ford; James Shepherd; Chris Packard; Brendan M Buckley; J Wouter Jukema; Alice H Lichtenstein; Ernst J Schaefer
Journal:  J Lipid Res       Date:  2010-01       Impact factor: 5.922

3.  The SLIM Study: Slo-Niacin® and Atorvastatin Treatment of Lipoproteins and Inflammatory Markers in Combined Hyperlipidemia.

Authors:  Robert H Knopp; Barbara M Retzlaff; Brian Fish; Alice Dowdy; Barbara Twaddell; Thuy Nguyen; Pathmaja Paramsothy
Journal:  J Clin Lipidol       Date:  2009       Impact factor: 4.766

4.  Understanding hypertriglyceridemia in women: clinical impact and management with prescription omega-3-acid ethyl esters.

Authors:  Thomas D Dayspring
Journal:  Int J Womens Health       Date:  2011-03-09

5.  Dietary ɛ-Polylysine Decreased Serum and Liver Lipid Contents by Enhancing Fecal Lipid Excretion Irrespective of Increased Hepatic Fatty Acid Biosynthesis-Related Enzymes Activities in Rats.

Authors:  Ryota Hosomi; Daiki Yamamoto; Ren Otsuka; Toshimasa Nishiyama; Munehiro Yoshida; Kenji Fukunaga
Journal:  Prev Nutr Food Sci       Date:  2015-03-31

6.  Intercorrelations of lipoprotein subfractions and their covariation with lifestyle factors in healthy men.

Authors:  Alexandr Parlesak; Joachim Eckoldt; Karl Winkler; Christian J Bode; Christian Schäfer
Journal:  J Clin Biochem Nutr       Date:  2014-04-04       Impact factor: 3.114

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.